证券代码：600056 证券简称：中国医药 公告编号：临 2025-052 号 中国医药健康产业股份有限公司 关于子公司药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的两份克林霉素磷酸酯注射液（以下简称"该药 品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。 现将有关情况公告如下： 一、通知书基本信息 药品名称：克林霉素磷酸酯注射液 受理号：CYHB2450258、CYHB2450259 通知书编号：2025B02988、2025B02987 剂型：注射剂 规格：4ml:0.6g（按 C₁₈H₃₃ClN₂O₅S 计）、2ml:0.3g（按 C₁₈H₃₃ClN₂O₅S 计） 注册分类：化学药品 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医 疗器械审评审 ...

Financial Performance - Whirlpool expects a net profit of approximately 205 million yuan for the first half of 2025, an increase of about 174 million yuan or approximately 559% year-on-year [2] - Chipmotion Technology anticipates a net profit between 138 million to 169 million yuan for the first half of 2025, representing a year-on-year growth of approximately 144.46% to 199.37% [2] Mergers and Acquisitions - China Shipbuilding's absorption merger with China Shipbuilding Industry Corporation has been approved by the Shanghai Stock Exchange, pending further regulatory approvals [3] - Guotou Zhonglu plans to acquire 100% of China Electronic Engineering Design Institute through a share issuance, which constitutes a major asset restructuring [4] Shareholder Actions - Aotewei's actual controllers plan to transfer 4.99% of the company's shares, totaling 15.75 million shares, due to personal funding needs [5] - Yaguang Technology's chairman has been placed under detention, but the company's operations remain normal [5] Industry Developments - Ningbo Port expects a 9.8% year-on-year increase in container throughput for the first half of 2025 [8] - Three Trees anticipates a net profit growth of 80.94% to 119.04% for the first half of 2025 [8] - Zhuhai Group expects a net profit increase of 50.97% to 75.23% for the first half of 2025 [8] Project Wins - Sanxing Medical's subsidiary has pre-qualified for a 306 million yuan project with Southern Power Grid [8] - Hopu Co., Ltd. has jointly won a 449 million yuan shared energy storage demonstration project [8] - Hongsheng Huayuan's subsidiary has pre-qualified for an 1.127 billion yuan project with Southern Power Grid [8]

证券代码：600056 证券简称：中国医药 公告编号：临 2025-051 号 中国医药健康产业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 规格：5ml:25mg（按 C20H29N5O3计）、10ml:50mg（按 C20H29N5O3计） 上市许可持有人：天方药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 （一）盐酸乌拉地尔由武田制药研发，于 1981 年在德国上市，于 1993 年在 国内获准上市。主要用于治疗高血压危象（如血压急剧升高），重度和极重度高 血压以及难治性高血压；用于控制围手术期高血压。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的两份盐酸乌拉地尔注射液（以下简称"该药品"） 《药品注册证书》，现将有关情况公告如下： 一、注 ...

Core Viewpoint - China Medical (600056) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) received two drug registration certificates for hydrochloride urapidil injection from the National Medical Products Administration, which is primarily used for treating hypertensive crises and severe hypertension [1] Company Summary - The drug is intended for the treatment of hypertensive crises, severe and extremely severe hypertension, as well as refractory hypertension, and for controlling perioperative hypertension [1] - The registration application was accepted by the National Medical Products Administration in February 2024, with research and development investments amounting to approximately 7.31 million yuan [1] - The company aims to enrich its cardiovascular medication product line with this new registration [1] Industry Summary - A total of 28 domestic production enterprises have obtained approval for this drug, with the total domestic sales in 2023 estimated at approximately 1.072 billion yuan and projected to be around 801 million yuan in 2024 [1] - Future sales may face risks of not meeting expectations due to policy and market environment influences [1]

Group 1 - The second China Pharmaceutical Health Industry Development Conference highlighted the innovative capabilities of Zibo's pharmaceutical sector, showcasing a complete chain from research and development to clinical application [1] - The event featured a visit to Shandong Shibo Jindu Pharmaceutical, where representatives observed modern drug production lines and quality control systems, emphasizing the transition from laboratory innovations to practical medical solutions [1] - A notable innovation presented was the "Liwei Wuling Pian," a drug addressing liver damage, which signifies Zibo's advancements in pharmaceutical innovation [1] Group 2 - The conference included a public health initiative, "Experts Going to the Grassroots," where specialists from various medical fields provided free consultations, demonstrating a commitment to community health and the "Healthy China" strategy [2] - The event facilitated one-on-one consultations for chronic disease management, cancer prevention, and traditional Chinese medicine, reflecting a holistic approach to patient care [2] - The collaboration between academic events and grassroots health services underscores the importance of accessible healthcare and the responsibility of medical professionals to engage with the community [2]

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **pharmaceutical industry**, particularly the **oncology treatment market** in China, which is projected to reach **$440 billion** by **2028**, accounting for **25%** of the total drug market [1][2]. Core Insights and Arguments - **Growth in Oncology Market**: The oncology treatment market is expected to grow significantly over the next five years, with **double antibodies (双抗)** and **antibody-drug conjugates (ADC)** emerging as key directions for next-generation cancer therapies [1][2]. - **China's Leading Position**: Chinese companies have established a leading position in the ADC and double antibody fields, with products like **AK112** from **Kangfang Biotech** being the first validated double antibody product [2][4]. - **Investment in Innovation**: Approximately **40%** of emerging therapy pipelines are concentrated in China, with major deals enhancing market confidence, as companies like **BeiGene** and **Innovent** have begun to achieve profitability [1][7]. - **MNC Challenges**: Large multinational pharmaceutical companies face challenges such as patent cliffs and insufficient product lines, leading to a strong demand for mergers and acquisitions (M&A) and business development (BD) activities [1][11]. - **BD Activity**: The average upfront payment for BD transactions in China has surpassed global levels, indicating high product quality and market recognition [15][8]. Additional Important Content - **Market Dynamics**: The PD-1 market is projected to grow from **$50-60 billion** in **2024** to **$100 billion** by **2029**, with double antibodies expected to capture some of this market share due to their effectiveness against cold tumors [5][6]. - **ADC Development Trends**: The ADC field is exploring new toxins, conjugation methods, and multi-target combinations, with a significant increase in clinical trial numbers [6][14]. - **Policy Support**: Recent policies have expanded the commercial insurance directory, allowing for better pricing strategies and faster hospital admission processes, which are crucial for the development of innovative drugs [16][19]. - **Market Size and Growth Projections**: The domestic innovative drug market is currently valued at approximately **¥260 billion**, with expectations of growth rates between **30% and 40%** in the coming years, potentially reaching **¥900 billion to ¥1 trillion** [17][18]. - **Commercialization Environment**: The commercialization environment in China is improving, with the penetration rate of oncology drugs increasing from **50%** to **80-90%** [20]. - **Future Development Factors**: Key factors for future growth include ongoing policy support, increasing profitability, and the potential emergence of Chinese multinational companies [23]. Companies with Potential - Notable companies with significant potential include **Innovent**, **Ascentage**, **Kangfang**, and **Hengrui**, which have promising product pipelines in oncology and other therapeutic areas [26]. Conclusion - The Chinese pharmaceutical industry, particularly in innovative drug development, is poised for substantial growth, driven by strong market dynamics, supportive policies, and a focus on advanced therapeutic modalities like ADCs and double antibodies.

Core Viewpoint - China National Pharmaceutical Group Corporation (referred to as "the company" or "China Pharmaceutical") has decided to waive its right of first refusal for the 24% equity stake in Chongqing Medical Health Industry Co., Ltd. (referred to as "Chongqing Medical Health") held by its shareholder Chongqing Yufu Holdings Group Co., Ltd. [1][4] Group 1: Equity Transfer Details - Chongqing Yufu intends to publicly transfer its 24% equity stake in Chongqing Medical Health, with a base price of 2,206.11024 million yuan, to be paid in a lump sum [1][2] - The transfer is being conducted through the Chongqing United Property Rights Exchange, and the final buyer has not yet been determined [2] - Chongqing Medical Health has a registered capital of 1 billion yuan, with a shareholding structure of 49% held by Chongqing Yufu, 24% by China General Technology (Group) Holding Co., Ltd., and 27% by China Pharmaceutical [2] Group 2: Company Strategy and Decision - The company is focusing on an integrated transformation and upgrade strategy, concentrating resources on core business areas such as technology innovation and industrial transformation [2][4] - The decision to waive the right of first refusal is based on a comprehensive assessment of the company's current business structure and future plans, aiming for sustainable high-quality development [2][4] - The waiver of the right of first refusal will not change the company's consolidated financial reporting scope or its shareholding percentage in Chongqing Medical Health, and it will not adversely affect the company's financial and operational status [4]

中国医药健康产业股份有限公司股东大会会议文件 北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 证券代码：600056 证券简称：中国医药 2025 年第四次临时股东大会 会议资料 2025 年 6 月 23 日 中国医药健康产业股份有限公司股东大会会议文件 关于放弃参股公司24%股权优先购买权的议案 各位股东： 近日，中国医药健康产业股份有限公司(以下简称"公 司"或"中国医药")收到参股公司重庆医药健康产业有限 公司（以下简称"重庆医健"）股东重庆渝富控股集团有限 公司(以下简称"重庆渝富"，持有重庆医健 49%股权)《关于 重庆渝富控股集团有限公司拟公开挂牌转让重庆医药健康 产业有限公司股权的告知函》，重庆渝富拟采取公开挂牌方 式转让其所持重庆医健 24%股权，并就本次拟转让事项请公 司确定是否行使优先购买权。6 月 18 日，重庆渝富在重庆联 合产权交易所正式公开挂牌转让其所持重庆医健 24%股权， 公开征集受让方。挂牌公告显示，重庆渝富本次股权转让底 价为 220,611.024 万元，价款支付方式为一次性支付。 1 中国医药健康产业股份有限公司股东大会会议文件 结合公司实际情况及整体工作安 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-050 号 中国医药健康产业股份有限公司 2024年度末期权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.08565元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/9 | － | 2025/7/10 | 2025/7/10 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日召开的2024年年度股东大会审议通过。 加上 2024 年中期已派发的现金红利每股 0.02174 元（含税），合计按每股 0.10739 元（含税）向全体股东派发 2024 年度现金红利，总金额为 160,642,526.14 元。 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 ...

中国医药健康产业股份有限公司股东大会会议文件 证券代码：600056 证券简称：中国医药 2025 年第四次临时股东大会 会议资料 2025 年 6 月 23 日 中国医药健康产业股份有限公司股东大会会议文件 北京市丰台区西营街 1 号院 1 区 1 号楼 28 层 中国医药健康产业股份有限公司股东大会会议文件 关于放弃参股公司24%股权优先购买权的议案 各位股东： 近日，中国医药健康产业股份有限公司(以下简称"公 司"或"中国医药")收到参股公司重庆医药健康产业有限 公司（以下简称"重庆医健"）股东重庆渝富控股集团有限 公司(以下简称"重庆渝富"，持有重庆医健 49%股权)《关于 重庆渝富控股集团有限公司拟公开挂牌转让重庆医药健康 产业有限公司股权的告知函》，重庆渝富拟采取公开挂牌方 式转让其所持重庆医健 24%股权，并就本次拟转让事项请公 司确定是否行使优先购买权。6 月 18 日，重庆渝富在重庆联 合产权交易所正式公开挂牌转让其所持重庆医健 24%股权， 公开征集受让方。挂牌公告显示，重庆渝富本次股权转让底 价为 220,611.024 万元，价款支付方式为一次性支付。 （三）标的企业情况 1 中国医药 ...